UNIV OF MI HOSPITALS & HLTH CTRS
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $435M
- Transactions
- 26,838
- Companies
- 40
- Average per transaction
- $16,209
Who reported the payments
| Sanofi | $97,025,080 |
| AstraZeneca | $34,911,410 |
| Janssen Research & Development, LLC | $25,997,820 |
| Merck | $23,671,546 |
| AbbVie | $18,177,411 |
| Novartis | $17,527,327 |
| Takeda Pharmaceuticals U.S.A., Inc. | $15,513,633 |
| Genentech, Inc. | $14,768,547 |
| E.r. Squibb & Sons, L.L.C. | $13,051,316 |
| Pfizer | $10,176,069 |
| Regeneron | $8,385,260 |
| Eli Lilly | $7,896,325 |
| Amgen | $7,811,000 |
| Medtronic | $7,029,675 |
| Novo Nordisk AS | $6,885,269 |
| Astrazeneca AB | $6,363,384 |
| CSL Behring | $4,619,544 |
| Blueprint Medicines Corporation | $4,420,690 |
| Bristol Myers Squibb | $4,078,314 |
| Edwards Lifesciences | $3,987,570 |
| Beigene, Ltd. | $3,715,502 |
| Travere Therapeutics, Inc. | $3,287,657 |
| Sanofi US Services Inc. | $2,883,426 |
| Boehringer Ingelheim | $2,851,277 |
| Boston Scientific | $2,664,221 |
| Astrazeneca UK Limited | $2,655,271 |
| Gilead | $2,535,012 |
| Teva Pharmaceuticals USA, Inc. | $2,500,611 |
| Incyte Corporation | $2,458,577 |
| Astellas Pharma Global Development | $2,242,598 |
| Bausch Health US, LLC | $2,146,307 |
| Ipsen Biopharmaceuticals, Inc | $1,977,173 |
| Siemens Medical Solutions USA, Inc. | $1,969,069 |
| Servier Bioinnovation | $1,937,973 |
| Seagen Inc. | $1,916,557 |
| Agios Pharmaceuticals, Inc. | $1,793,313 |
| Histosonics, Inc. | $1,773,719 |
| Eisai Inc. | $1,724,423 |
| Abbott | $1,601,000 |
| F. Hoffmann-la Roche AG | $1,478,521 |